Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Constellation Brings In Series B Totaling $22 Million, Including GSK Investment

This article was originally published in The Pink Sheet Daily

Executive Summary

Involvement by GSK's venture arm SR One enables Constellation to keep pace with epigenetics competitor Epizyme, which is backed by Amgen and Astellas.

You may also be interested in...



Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet

For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.

GSK Teams Up With EpiZyme To Develop Epigenetic Drugs

The Cambridge, Mass., biotech, a leader in epigenetics, garners its first big pharma partner.

GSK Teams Up With EpiZyme To Develop Epigenetic Drugs

The Cambridge, Mass., biotech, a leader in epigenetics, garners its first big pharma partner.

Related Content

Topics

UsernamePublicRestriction

Register

PS070779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel